<DOC>
	<DOC>NCT02908074</DOC>
	<brief_summary>This is a 6 months, active treatment, extension study, open to subjects who have completed full 24 weeks in Study MBGS205 (A Phase IIb multicentre, double-blind, dose-ranging, randomised, placebo-controlled study evaluating safety and efficacy of BGS649 in male obese subjects with hypogonadotropic hypogonadism [HH]).The main purpose of Study MBGS206 is to evaluate bone mineral density and other long term safety and efficacy parameters in subjects after 12 months exposure with BGS649.</brief_summary>
	<brief_title>A 6 Month Safety Extension Study of MBGS205 Evaluating the Long Term Effects of BGS649 on Bone Mineral Density</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<criteria>Participating in Study MBGS205 and completion of the 24 week treatment period without meeting any discontinuation criteria of Study MBGS205 In opinion of the investigator has been compliant with the requirements of the Study MBGS205 protocol. Meeting any of the discontinuation criteria of initial Study MBGS205</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hypogonadotropic</keyword>
	<keyword>hypogonadism</keyword>
	<keyword>testosterone</keyword>
</DOC>